Trial · NCT01983553
Outcomes14
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Event Rate Per 100 Participant-years for Hospitalized Virologically-Confirmed Dengue (VCD) Cases Due to Any and Each Serotype Following Vaccination With Either CYD Dengue Vaccine or Placebo in the Previous Study (CYD23) | Year 1 to Year 4 post- 3rd vaccination at Month 12 in CYD23 | Analysis was performed on FupAS. | Events per 100 participant-years | NUMBER |
| PRIMARY | Number of Hospitalized VCD Cases Due to Any and Each Serotype (1, 2, 3 and 4) Following Vaccination With Either CYD Dengue Vaccine or a Placebo in a Previous Study (CYD23) | Year 1 to Year 4 post- 3rd vaccination at Month 12 in CYD23 | Analysis was performed on FupAS. | Cases | NUMBER |
| PRIMARY | Number of Episodes of Hospitalized VCD Due to Any and Each Serotype (1, 2, 3 and 4) Following Vaccination With Either CYD Dengue Vaccine or a Placebo in a Previous Study (CYD23) | Year 1 to Year 4 post- 3rd vaccination at Month 12 in CYD23 | Analysis was performed on FupAS. | Episodes | NUMBER |
| PRIMARY | Event Rate Per 100 Participant-years for Hospitalized VCD Cases Due to Any and Each Serotype Collected By Age Group (Aged: 4-5; 6-11 Years) Following Vaccination With Either CYD Dengue Vaccine or Placebo in a Previous Study (CYD23) | Year 1 to Year 4 post- 3rd vaccination at Month 12 in CYD23 | Analysis was performed on FupAS. Here, number analyzed signifies participants with available data for each specified category. | Events per 100 participant-years | NUMBER |
| PRIMARY | Number of Hospitalized VCD Cases Due to Any and Each Serotype (1, 2, 3 and 4) Collected By Age Group (Aged: 4-5; 6-11 Years) Following Vaccination With Either CYD Dengue Vaccine or Placebo in a Previous Study (CYD23) | Year 1 to Year 4 post- 3rd vaccination at Month 12 in CYD23 | Analysis was performed on FupAS. Here, number analyzed signifies participants with evaluable data for each specified category. | Cases | NUMBER |
| PRIMARY | Number of Episodes of Hospitalized VCD Due to Any and Each Serotype (1, 2, 3 and 4) Collected By Age Group (Aged: 4-5; 6-11 Years) Following Vaccination With Either CYD Dengue Vaccine or Placebo in a Previous Study (CYD23) | Year 1 to Year 4 post- 3rd vaccination at Month 12 in CYD23 | Analysis was performed on FupAS. Here, number analyzed signifies participants with evaluable data for each specified category. | Episodes | NUMBER |
| PRIMARY | Event Rate Per 100 Participant-years for Clinically Severe Hospitalized VCD Cases Due to Any and Each Serotype Following Vaccination With Either CYD Dengue Vaccine or Placebo in a Previous Study (CYD23) | Year 1 to Year 4 post- 3rd vaccination at Month 12 in CYD23 | Analysis was performed on FupAS. | Events per 100 participant-years | NUMBER |
| PRIMARY | Number of Clinically Severe Hospitalized VCD Cases Due to Any and Each Serotype (1, 2, 3 and 4) Following Vaccination With CYD Dengue Vaccine or Placebo in a Previous Study (CYD23) | Year 1 to Year 4 post- 3rd vaccination at Month 12 in CYD23 | Analysis was performed on FupAS. | Cases | NUMBER |
| PRIMARY | Number of Episodes of Clinically Severe Hospitalized VCD Due to Any and Each Serotype (1, 2, 3 and 4) Following Vaccination With CYD Dengue Vaccine or Placebo in a Previous Study (CYD23) | Year 1 to Year 4 post- 3rd vaccination at Month 12 in CYD23 | Analysis was performed on FupAS. | Episodes | NUMBER |
| PRIMARY | Number of Cases of Non-Serotype Specific Dengue Viremia Among Hospitalized VCD Cases Following Vaccination With CYD Dengue Vaccine or Placebo in Previous Study (CYD23) | During Year 1 to Year 4 post 3rd vaccination at Month 12 in CYD23 at each of the following time points: Anytime, 0-3 days, 4-7 days, 0-7 days, After 7 days during the sera sample collection time interval of 14 days | Analysis was performed on FupAS. Here, 'number analyzed' = number of hospitalized VCD episodes in the specified time period. | Participants | NUMBER |
| PRIMARY | Non-Serotype Specific Dengue Viremia Among Hospitalized VCD Cases Following Vaccination With CYD Dengue Vaccine or Placebo in Previous Study (CYD23) | Year 1 to Year 4 post-vaccination after 3rd vaccination at Month 12 in CYD23 at each of the following time points: Anytime, 0-3 days, 4-7 days, 0-7 days, After 7 days during the sample collection time interval of 14 days | Analysis was performed on FupAS. Here, 'number analyzed' = number of hospitalized VCD episodes in the specified time period. | log10 pfu/mL | MEAN |
| PRIMARY | Event Rate Per 100 Participant-years for Hospitalized VCD Cases Due to Any and Each Serotype and Meeting World Health Organization (WHO) 1997 Criteria Collected Following Either CYD Dengue Vaccine or Placebo in a Previous Study (CYD23) | Year 1 to Year 4 post- 3rd vaccination at Month 12 in CYD23 | Analysis was performed on FupAS. | Events per 100 participant-years | NUMBER |
| PRIMARY | Number of Hospitalized VCD Cases Due to Any and Each Serotype (1, 2, 3 and 4) and Meeting WHO 1997 Criteria Following Vaccination With CYD Dengue Vaccine or Placebo in a Previous Study (CYD23) | Year 1 to Year 4 post- 3rd vaccination at Month 12 in CYD23 | Analysis was performed on FupAS. | Cases | NUMBER |
| PRIMARY | Number of Episodes of Hospitalized VCD Cases Due to Any and Each Serotype (1, 2, 3 and 4) and Meeting WHO 1997 Criteria Following Vaccination With CYD Dengue Vaccine or Placebo in a Previous Study (CYD23) | Year 1 to Year 4 post- 3rd vaccination at Month 12 in CYD23 | Analysis was performed on FupAS. | Episodes | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01983553/outcomes